Gary Abrams, MD
Gastroenterology · Greenville, SCNPI 1770537573
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Novo Nordisk at 54.9% of the total. 2024 is the largest year on record at $2,713, 2.3 times the $1,177 reported in 2019.
Across 115 payments — averaging $42.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Novartis$697
- AbbVie$641
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$211
- Pfizer$197
- Johnson & Johnson$118
- plus $364 from 10 others
Across 111 payments — averaging $8291.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$648K
- Gilead$139K
- Intercept Pharma Europe Ltd.$75K
- Novartis$59K
What the payments were for
- Consulting fees$2,71355%
- Travel & lodging$4419%
- Food & beverage$1,76836%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 1 | $2,713 |
| Novartis | 5 | $697 |
| AbbVie(2 entities) | 49 | $641 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $211 |
| Pfizer | 14 | $197 |
| Johnson & Johnson | 9 | $118 |
| QOL Medical, LLC | 5 | $69 |
| Intercept Pharmaceuticals, Inc. | 4 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Shionogi Inc | 4 | $53 |
| Gilead | 2 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| UCB, Inc. | 2 | $24 |
| Lucid Diagnostics Inc. | 1 | $15 |
| Sanofi | 1 | $14 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$4,941 in reported general payments places this provider in the 65th percentile of 259 gastroenterology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Greenville
- Andre EaddyGreenville$212K
- Veeral OzaGreenville$199K
- Christina BauerGreenville$179K
- Joseph LebelGreenville$22K
- Michael RickoffGreenville$16K
- Joseph BaberGreenville$11K
- John EdmisonGreenville$10K
- Madhusudhan SunkavalliGreenville$9K
- Erin ForsterCharleston$788K
- Mark DeleggeCharleston$568K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.